Mikhail Kosiborod
Overview
Explore the profile of Mikhail Kosiborod including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
269
Citations
9555
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferreira J, Vasques-Novoa F, Angermann C, Biegus J, Collins S, Kosiborod M, et al.
Eur J Heart Fail
. 2025 Feb;
PMID: 39980254
Aims: Empagliflozin improves outcomes in acute heart failure (AHF). Patients with AHF and low blood pressure (BP) have poor prognosis. Whether empagliflozin is effective and safe in patients with AHF...
2.
Barnard-Kelly K, Battelino T, Brosius F, Ceriello A, Cosentino F, Gavin 3rd J, et al.
Cardiovasc Diabetol
. 2025 Feb;
24(1):68.
PMID: 39920737
Recent clinical practice guidelines for diabetes, obesity, cardiovascular disease (CVD) and chronic kidney disease (CKD) emphasise a holistic, person-centred approach to care. However, they do not include recommendations for the...
3.
Desai A, Vaduganathan M, Claggett B, Kulac I, Jhund P, Cunningham J, et al.
J Am Coll Cardiol
. 2024 Oct;
85(2):106-116.
PMID: 39352340
Background: Patients with heart failure (HF) and a recent worsening heart failure (WHF) event are known to be at high risk of recurrent hospitalization and death, regardless of ejection fraction....
4.
Patel R, Wadid M, Makwana B, Kumar A, Khadke S, Bhatti A, et al.
JACC Heart Fail
. 2024 Aug;
12(11):1814-1826.
PMID: 39207323
Background: Although the use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) in patients with obesity and heart failure with preserved ejection fraction (HFpEF) has demonstrated improvement in cardiovascular outcomes, the...
5.
Weir M, Rossignol P, Pitt B, Lund L, Coats A, Filippatos G, et al.
Am J Nephrol
. 2024 Aug;
55(6):672-689.
PMID: 39159624
Introduction: Renin-angiotensin-aldosterone system inhibitor (RAASi; including mineralocorticoid receptor antagonists [MRAs]) benefits are greatest in patients with heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD); however, the...
6.
Bonaca M, Bhatt D, Simon T, Fox K, Mehta S, Harrington R, et al.
J Am Coll Cardiol
. 2024 Apr;
83(17):1627-1636.
PMID: 38658101
Background: Ticagrelor reduced major adverse cardiovascular events (MACE) and increased bleeding in patients with type 2 diabetes mellitus (T2DM) and coronary artery disease. Limb events including revascularization, acute limb ischemia...
7.
Rajagopalan S, Vergara-Martel A, Zhong J, Khraishah H, Kosiborod M, Neeland I, et al.
Circulation
. 2024 Apr;
149(16):1298-1314.
PMID: 38620080
Urban environments contribute substantially to the rising burden of cardiometabolic diseases worldwide. Cities are complex adaptive systems that continually exchange resources, shaping exposures relevant to human health such as air...
8.
Gavin J, Rodbard H, Battelino T, Brosius F, Ceriello A, Cosentino F, et al.
Diabetes Res Clin Pract
. 2024 Apr;
211:111666.
PMID: 38616041
There is a mounting clinical, psychosocial, and socioeconomic burden worldwide as the prevalence of diabetes, cardiovascular disease (CVD), and chronic kidney disease (CKD) continues to rise. Despite the introduction of...
9.
Schnell O, Barnard-Kelly K, Battelino T, Ceriello A, Elding Larsson H, Fernandez-Fernandez B, et al.
Cardiovasc Diabetol
. 2024 Mar;
23(1):104.
PMID: 38504284
The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for...
10.
Ceriello A, Rodbard H, Battelino T, Brosius F, Cosentino F, Green J, et al.
Cardiovasc Diabetol
. 2023 Oct;
22(1):277.
PMID: 37833776
In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic...